Table 1 Clinical characteristics between type 1 and type 2 papillary renal cell carcinoma
Type 1 PRCC | Type 2 PRCC | P | |
|---|---|---|---|
Gender | |||
Male | 18 (75.0%) | 20 (71.4%) | 0.772 |
Female | 6 (25.0%) | 8 (28.6%) | |
Age (years) | 53.4 ± 12.6 | 55.8 ± 15.5 | 0.552 |
Tumor size (cm) | 4.6 ± 2.26 | 4.9 ± 2.76 | 0.683 |
Cell-based immunotherapya | |||
Yes | 3 (12.5%) | 5 (17.9%) | 0.882 |
No | 21 (87.5%) | 23 (82.1%) | |
WHO/ISUP grade | |||
G1/G2 | 22 (91.7%) | 16 (57.1%) | 0.005 |
G3/G4 | 2 (8.3%) | 12 (42.9%) | |
Tumor stage (T) | |||
T1/T2 | 20 (83.3%) | 16 (57.1%) | 0.041 |
T3/T4 | 4 (16.7%) | 12 (42.9%) | |
Type of surgery | |||
Radical nephrectomy | 8 (33.3%) | 17 (60.7%) | 0.049 |
Partial nephrectomy | 16 (66.7%) | 11 (39.3%) | |
Surgical approach | |||
Open surgery | 3 (12.5%) | 9 (32.1%) | 0.094 |
Laparoscopic surgery | 21 (87.5%) | 19 (67.9%) | |
Disease progression | |||
Yes | 1 (4.0%) | 9 (33.3%) | 0.028 |
No | 22 (96.0%) | 18 (66.7%) | |
Death from tumor | |||
Yes | 0 (0.0%) | 6 (22.2%) | 0.048 |
No | 23 (100.0%) | 21 (77.8%) | |